The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- PMAT, OPMA Petition MREAC on Pass/Fail Criteria for MR Exam
April 11, 2011
- Korosho Requires Revision of Package Insert for Hib Vaccine, Pneumococcal Vaccines
April 11, 2011
- ASKA Resumes Production, Shipment of Thyradin-S Tablets
April 4, 2011
- Daiichi Sankyo's Direct Xa Inhibitor Rixiana Recommended for Approval by PAC
April 4, 2011
- Damage at Fukushima Plant to Affect 3 Brands: Ajinomoto Pharm.
April 4, 2011
- Eisai Announces Approval of Halaven in Europe
April 4, 2011
- Daiichi Sankyo Resumes Production at Some Facilities
April 4, 2011
- Fingolimod Approved for MS in Europe: Novartis
April 4, 2011
- Shipments of Ensure to Resume in Late May: Abbott Japan
April 4, 2011
- CHMP to Assess Benefit-Risk Balance of Pioglitazone
April 4, 2011
- Asahi Kasei Licenses XIAFLEX from Auxilium
April 4, 2011
- MREAC Calls For “Consideration”in Post-disaster MR Activities
April 4, 2011
- Kowa, MEDRx Announce Agreement for Etodolac Patch
April 4, 2011
- Recruiting Is the Lifeblood of Any Company
April 4, 2011
- Meiji Seika Licenses Ziprasidone from RaQualia
April 4, 2011
- Vaccination with Prevnar, ActHIB to Resume April 1
April 4, 2011
- R-Tech Ueno Licenses Unoprostone to Sucampo
April 4, 2011
- Pharma Design Licenses Part of Its Rights to Cancer Transcription Factors to Yakult
April 4, 2011
- BI Ties Up with MorphoSys to Manufacture Biopharmaceuticals
April 4, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
April 4, 2011
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…